000 03178naa a22005057i 4500
001 UMUN-OA-20261005-MLS-064
003 local
005 20261005174906.0
006 m o d
007 cr||||||||||||
008 261005s2022 xx o u000 0 eng d
024 7 _a10.1186/s12943-022-01663-0
_2doi
035 _a(local)EuropePMC:PMC9547409
040 _alocal
_beng
_clocal
041 0 _aeng
100 0 _aJunru Lu
_eauthor.
245 1 4 _aThe journey of CAR-T therapy in hematological malignancies. /
_cJunru Lu; Guan Jiang.
264 1 _a[Place of publication not identified] :
_bBMC,
_c2022.
300 _a1 online resource (1 article).
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
500 _aPublication type: Review article.
500 _aLinked open-access copy: published version.
506 0 _aOpen access; no subscription required for the linked open-access version.
_fUnrestricted online access
_2star
520 3 _aChimeric antigen receptor T (CAR-T) cells therapy has revolutionized the treatment paradigms for hematological malignancies, with multi-line therapy-refractory patients achieving durable complete remissions (CR) and relatively high objective response rate (ORR). So far, many CAR-T products, such as Kymriah, Yescarta and Tecartus, have been developed and got the unprecedented results. However, some patients may relapse afterwards, driving intense investigations into promoting the development of novel strategies to overcome resistance and mechanisms of relapse. Notable technical progress, such as nanobodies and CRISPR-Case9, has also taken place to ensure CAR-T cell therapy fully satisfies its medical potential. In this review, we outline the basic principles for the development and manufacturing processes of CAR-T cell therapy, summarize the similarities and differences in efficacy of different products as well as their corresponding clinical results, and discuss CAR-T immunotherapy combined with other clinical effects of drug therapy.
540 _aCreative Commons Attribution. See the linked licence for the applicable terms.
_uhttps://creativecommons.org/licenses/by/4.0/
546 _aIn English.
588 0 _aDescription generated from Europe PMC bibliographic metadata retrieved on 5 October 2026; full text linked from the source.
590 _aCourse allocation: B. Sc. Medical Laboratory Science.
650 4 _aHematological malignancies
650 4 _aTargeted Therapy
650 4 _aCombinatorial Therapy
650 4 _aDrug Product
650 4 _aCar-t Cell Therapy
653 _aB. Sc. Medical Laboratory Science
653 _aUMUN open access collection
653 _ahematology
655 4 _aReview articles.
700 0 _aGuan Jiang
_eauthor.
773 0 _tMolecular cancer
_gVol. 21, no. 1, (2022), pages/article 194
_x1476-4598
856 4 0 _uhttps://europepmc.org/articles/PMC9547409
_yRead open-access publication
_zOpen access.
_70
884 _aCourse selection and automated MARC21 enrichment from Europe PMC metadata.
_g20261005
_khttps://europepmc.org/articles/PMC9547409
_qlocal
942 _n0
999 _c1206
_d1206